Drug
S095018
S095018: highest development phase Phase 1/2, developed by Servier. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Servier
Trials
| Drug | Phase | Indication |
|---|---|---|
| S095018 NCT06162572 | Phase 1/2 | Non-small Cell Lung Cancer (NSCLC) |
Latest
No recent events.
Follow S095018 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.